Coloplast A/S CLPBY

Health CareHealthcare Equipment & SuppliesDenmark

Last close 6.75 USD on Nov 2, 2026, −19.6% year to date

Quant rating

Quant rating D Rank 163 of 211 in Health Care

Growth D 187 of 211
Valuation B 61 of 211
Quality C 138 of 211
Revisions D 180 of 211
Momentum C 85 of 211

Wall Street consensus Hold (3.00)Average target 6.70 USD −0.7%

Historical valuation

Multiples use consensus estimates for the next twelve months. The dashed line is the 5-year average.

Key data

Market cap: 15.1B
Enterprise value: 18.6B
52-week range: 5.64 – 9.70
3-year range: 5.64 – 14.30
Dividend yield: 4.97%
Beta (5 years): 0.74
Shares outstanding: 210M
Next earnings: Nov 5, 2026

About the company

Coloplast A/S is a Denmark-based company active within the healthcare sector. It is engaged in the development, marketing and sale of intimate healthcare products and services, targeting people with diseases of private and personal nature. Its operations are structured into four business areas: Ostomy Care offering products for people whose intestinal outlet has been rerouted through the abdominal wall, Continence Care products for people suffering from diseases of and damage to the urinary system, Urology Care products for people suffering from diseases of and damage to the kidneys, the urinary system or the male reproductive system and Wound & Skin Care for the treatment of chronic wounds and skin care products for prevention and treatment. The Company supplies products to hospitals, institutions as well as wholesalers and pharmacies.

Growth and profitability fiscal year ends September 30

Growth and profitability by fiscal year
	2025	2024	2023	2022	2021	5Y avg
Revenue (mil)	4,382	4,038	3,474	2,977	3,025	–
Revenue growth	8.5%	16.2%	16.7%	−1.6%	3.6%	8.5%
EPS (basic, normalized)	–	–	–	–	–	–
EPS growth	–	–	–	–	–	–
Gross margin	68.0%	67.6%	66.6%	68.8%	68.5%	67.9%
Net margin	13.0%	18.7%	19.5%	20.8%	24.8%	19.4%
ROE	21.3%	28.7%	37.4%	57.2%	62.0%	41.3%

Balance sheet, last quarter
Cash & short-term investments (mil)	125
Current ratio	1.56x
Long-term debt (mil)	3,198
Net debt (mil)	3,513
Total equity (mil)	2,043
Net debt / equity	1.72x
Net debt / EBITDA	2.55x

Estimates and valuation

Consensus estimates and implied multiples
	Sales (mil)			EBITDA (mil)			EPS
Fiscal year	Mean est.	Growth	EV/Sales	Mean est.	Growth	EV/EBITDA	Mean est.	Growth	P/E
2025 actual	4,382	+8.5%	4.2x	1,380	–	13.5x	0.04	–	177.6x
2026	4,693	+7.1%	4.0x	1,406	+1.9%	13.2x	0.39	+926.3%	17.3x
2027	4,693	0.0%	4.0x	1,406	0.0%	13.2x	0.39	0.0%	17.3x

Estimate revisions

Change in consensus estimates over 1, 3 and 6 months
	Sales				EPS
Fiscal year	Estimate (mil)	1M	3M	6M	Estimate	1M	3M	6M
2026	4,693	0.0%	0.0%	–	0.39	0.0%	−4.9%	–
2027	4,693	+0.9%	0.0%	–	0.39	0.0%	−4.9%	–
2028	–	–	–	–	–	–	–	–

Earnings surprises EPS beat in 1 of the last 4 quarters

Reported results versus consensus, last 10 fiscal quarters
Quarter ended	FQ-9	FQ-8	FQ-7	FQ-6	FQ-5	FQ-4	FQ-3	Dec 2025	Mar 2026	Jun 2026
Sales reported (mil)	–	–	–	–	–	–	–	1,098	1,110	1,144
Sales mean (mil)	–	–	–	–	–	–	–	–	–	1,108
Surprise	–	–	–	–	–	–	–	–	–	+3.2%
EPS reported	–	–	–	–	–	–	–	0.10	0.10	0.10
EPS mean	–	–	–	–	–	–	–	–	–	0.09
Surprise	–	–	–	–	–	–	–	–	–	+13.3%

Peer comparison Healthcare Equipment & Supplies

Peers in the same industry group, by market capitalization
Company	Market cap	Net debt/EBITDA	Net margin	P/B	FY1 P/E	FY2 P/E	FY1 EV/EBITDA	FY2 EV/EBITDA
CLPBY Coloplast A/S	15.1B	2.55x	13.0%	8.12x	17.3x	17.3x	13.2x	13.2x
ESLOY Essilorluxottica SA	96.8B	–	8.1%	2.19x	26.0x	24.2x	12.8x	12.0x
COO The Cooper Companies, Inc.	11.7B	1.94x	9.2%	1.40x	13.5x	13.1x	10.6x	10.2x
ALGN Align Technology, Inc.	10.9B	−1.01x	10.2%	2.54x	13.8x	12.6x	8.6x	8.3x
LNTH Lantheus Holdings, Inc.	6.6B	−0.04x	15.2%	4.99x	18.6x	15.5x	13.3x	10.8x
MMSI Merit Medical Systems Inc	5.1B	0.65x	8.5%	2.89x	19.4x	18.1x	12.7x	11.6x
Mean		0.82x	10.7%	3.69x	18.1x	16.8x	11.9x	11.0x
Median		0.65x	9.7%	2.72x	18.0x	16.4x	12.8x	11.2x

Technical analysis

1M+9.2%
3M+0.7%
1Y−22.2%
3Y−32.6%

Financial statements in millions of USD

Income statement in millions of USD, fiscal years

Income statement, Coloplast A/S, fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Total revenue	4,382	4,038	3,474	2,977	3,025	2,920
Cost of revenue	1,404	1,309	1,159	930	952	934
Gross profit	2,978	2,729	2,315	2,048	2,073	1,986
Selling, general & administrative expenses	1,518	1,394	1,138	963	928	906
Research & development	141	129	117	108	111	104
Depreciation/amortization	127	117	92.6	72.0	51.8	58.9
Interest expense (income), operating	–	–	–	–	–	–
Unusual expense (income)	81.0	−7.8	5.4	59.6	31.1	0
Other operating expenses	−14.3	0.1	−3.1	−6.5	−6.9	−4.6
Operating income	1,125	1,096	965	852	958	922
Net interest income (expense)	−146	−128	−100.0	−35.2	15.6	−56.7
Gain (loss) on sale of assets	–	–	–	–	–	–
Other non-operating income (expense)	−10.5	−12.7	−10.9	−8.4	−3.4	−4.4
Net income before taxes	968	955	854	808	970	861
Provision for taxes	396	201	176	187	219	200
Minority interest	–	–	–	–	–	–
Equity in affiliates	–	–	–	–	–	–
U.S. GAAP adjustment	–	–	–	–	–	–
Net income before extraordinary items	572	755	678	621	751	661
Extraordinary items	–	–	–	–	–	–
Net income	572	755	678	621	751	661
EBIT, normalized	1,206	1,088	971	911	989	922
EBITDA, normalized	1,434	1,281	1,122	1,034	1,113	1,056
Basic EPS, normalized	–	–	–	–	–	–

Balance sheet in millions of USD, fiscal years

Balance sheet, Coloplast A/S, fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Assets
Cash & short-term investments	149	118	129	83.5	105	92.1
Receivables	814	829	726	614	579	553
Total inventory	616	549	499	420	378	351
Prepaid expenses	64.6	64.8	54.5	38.6	26.8	25.7
Other current assets	0	0	0	0	0	0
Total current assets	1,643	1,560	1,409	1,157	1,089	1,022
Property, plant & equipment	1,114	982	848	679	683	618
Goodwill	3,039	2,894	2,832	1,885	316	311
Intangibles	1,648	1,637	1,600	1,117	253	61.1
Long-term investments	14.1	11.1	9.2	6.7	6.4	4.3
Note receivable	53.6	4.2	5.5	4.1	4.0	3.8
Other long-term assets	92.3	93.2	125	88.9	116	105
Total assets	7,603	7,181	6,829	4,938	2,466	2,125
Liabilities
Accounts payable	208	227	183	164	161	128
Payable/accrued	–	–	–	–	–	–
Accrued expenses	1.3	1.0	1.0	0.8	2.3	2.0
Short-term debt	0	0	0	0	0	0
Current portion of long-term debt	407	797	1,042	244	364	207
Other current liabilities	406	499	1,087	558	456	446
Total current liabilities	1,023	1,524	2,313	967	983	784
Long-term debt	3,152	2,583	1,733	2,223	69.9	67.7
Minority interest	–	–	–	–	–	–
Other liabilities	895	394	330	654	142	108
Total liabilities	5,069	4,501	4,376	3,844	1,195	959
Shareholders' equity
Preferred stock	–	–	–	–	–	–
Common stock	35.8	34.1	32.3	28.5	33.6	34.0
Additional paid-in capital	–	–	–	–	–	–
Retained earnings (accumulated deficit)	2,779	2,871	2,585	1,130	1,306	1,182
Treasury stock	–	–	–	–	–	–
Other equity	−280	−225	−164	−65.3	−67.4	−49.6
Total equity	2,534	2,680	2,453	1,093	1,272	1,166
Total liabilities & shareholders' equity	7,603	7,181	6,829	4,938	2,466	2,125

Cash flow statement in millions of USD, fiscal years

Cash flow statement, Coloplast A/S, fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Operating activities
Net income	1,132	1,093	960	849	958	922
Depreciation, depletion & amortization	228	193	152	123	123	134
Deferred taxes	–	–	–	–	–	–
Non-cash items	22.3	−13.7	−31.2	7.4	−4.8	−21.3
Changes in working capital	−338	−860	−481	−307	−253	−285
Cash from operations	1,045	413	599	672	824	749
Investing activities
Capital expenditures	−224	−201	−176	−150	−306	−147
Other investing cash flows	27.7	1.5	−1,094	−1,401	−7.0	4.7
Cash from investing	−197	−200	−1,270	−1,551	−313	−142
Financing activities
Financing cash flow items	–	–	–	68.7	–	–
Cash dividends paid	−779	−705	−602	−533	−596	−569
Issuance (retirement) of debt, net	–	–	–	–	–	–
Other financing cash flows	−36.0	478	1,349	1,333	102	−38.6
Cash from financing	−815	−227	747	869	−495	−607
Foreign exchange effects	−7.5	−4.6	−5.2	4.9	3.1	−5.4
Net change in cash	25.0	−18.4	70.5	−4.5	19.5	−5.2
Free cash flow	820	212	423	522	518	603

Disclaimer

The financial data presented in this report is delayed and obtained from sources QDD Research believes to be reliable, including stock exchanges, SEDAR, and EDGAR. However, no representation or warranty is made as to the accuracy, completeness, or timeliness of the information. QDD Research accepts no liability for any errors, omissions, or financial losses arising from the use of this data.

This report is generated using a fully systematic and quantitative approach. All factor scores and the overall quant rating (ranging from D to A+) are derived from algorithmic models and are based solely on objective financial metrics. These scores are intended for informational purposes only and should not be interpreted as investment advice or a recommendation to buy, sell, or hold any securities.

QDD Research is not a registered investment advisor or broker-dealer and does not provide personalized financial advice. The content is not tailored to the specific investment goals, financial situation, or risk profile of any individual investor. We strongly encourage readers to consult with a licensed broker or investment advisor before making any investment decisions based on the information contained in this report.

Live quote provided by TradingView. Report data updated Nov 2, 2026 after market close.